Tagged with

China A roundup of top stories from China’s pharma industry, including BeiGene’s new US R&D and manufacturing facility; Merck’s purchase of investigational B-cell depletion therapy from Curon Biopharma, and the Chinese approval of AstraZeneca and Daiichi Sankyo’s gastric cancer therapy.   China’s BeiGene opens new clinical R&D and biologics manufacturing facility…

Mexico Mexico has become a major player in global manufacturing, attracting companies looking to bring supply chains closer to North American markets, but home-grown pharma companies are also capitalizing on the country’s manufacturing muscle, increasing capabilities while betting on quality and aiming for international markets. Recent PharmaBoardroom interviewees share their insights.…

Mexico Wiener Lab is a leader in diagnostics, with a strong focus on clinical chemistry, immunology, coagulation, and molecular biology. As Héctor Barillas Soto explains, the company has a significant presence in Mexico and Latin America and specializes in providing advanced diagnostic solutions for both small and large laboratories. Barillas Soto…

Hong Kong Chuen Yan Leung leads life science-focused venture capital firm Silver Dart Capital based out of Hong Kong and also serves as vice chairman of the Hong Kong Biotechnology Organization. In conversation, Leung outlines Silver Dart’s investments in growth-stage healthcare companies that are already scientifically de-risked and generating revenue; some of…

Mexico Adium Mexico, recently rebranded to reflect the identity of the broader Adium Group, represents no less than 25 percent of the LatAm group’s sales. General Director José Miguel Fonken Quiroga shares the affiliate’s number one status, stellar growth, vast portfolio, and plans to expand into OTC and vaccines. Fonkel also…

Hong Kong With its dual business approach – commercializing acquired products while developing a novel respiratory disease pipeline – Nuance Pharma, after closing Series D funding and establishing a solid revenue stream, has set its sights on Asia Pacific. Founder and CEO Mark Lotter, discusses the regulatory and talent acquisition challenges in…

China Dr James Xue, founder, chairman and CEO of CANbridge Pharmaceuticals shares the career journey that led him to China’s first rare disease-focused company and the role CANbridge is playing in shaping policies relating to rare diseases, such as the National Rare Disease List. Xue also outlines the company’s robust pipeline…

China Drawing on a wealth of Big Pharma experience, Jenny Zheng now leads China operations for Illumina, a global leader in genomics, specialising in DNA sequencing technology that drives innovation in healthcare, research, and personalised medicine. Illumina continues to see China as a crucial part of its global strategy due to…

Europe Contributing to the August 2024 edition of DIA’s Global Forum magazine, Magda Chlebus from the EFPIA, Steffen Thirstrup and Alberto Ganan Jimenez from the EMA, Katharina Nothelfer of AiCuris Anti-infective Cures, Pedro Franco of Merck Serono, Annette Bakker of CTF Europe, Tim Chesworth of AstraZeneca, Jeevan Virk of Novartis, Virginie…

Global DIA’s Sorcha McCrohan, contributing to the the August 2024 edition of DIA’s Global Forum magazine, reviews insights from the town hall meetings that brought together regulators from around the world at the organization’s Global Annual Meeting 2024.   Regulators worldwide recently convened in San Diego for DIA’s Global Annual Meeting 2024 to…

Hong Kong Prominent oncologist and chair of the clinical oncology department at the Chinese University of Hong Kong Professor Tony Mok comments on the potential  of the Antibody Drug Conjugates (ADC) platform and discusses boosting clinical trials in Hong Kong and the difficulties posed by a shortage of doctors in the territory.…

Switzerland Switzerland, home to industry giants like Novartis and Roche, boasts a thriving pharma industry that generates some seven percent of the country’s GDP, as well as a flourishing biotech scene. However, all is not so well in Switzerland’s domestic healthcare landscape, where surging insurance premiums and drug costs mean that…